Drug Profile
Research programme: protein therapeutics - Pieris Pharmaceuticals/Takeda
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pieris; Takeda
- Developer Pieris Pharmaceuticals; Takeda
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Germany (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA (Parenteral)
- 10 Jan 2011 Early research in Undefined indication in Germany (Parenteral)